Pfizer promotes BRAF mutation testing for lung cancer patients to expand use of BRAFTOVI® and MEKTOVI® combination therapy.
Pfizer is advocating for BRAF mutation testing in lung cancer patients to enhance the use of its drug combination, BRAFTOVI® and MEKTOVI®, which targets the BRAF V600E mutation in metastatic non-small cell lung cancer. Approved since last year, this combination may become standard care. Pfizer's Chief Oncology Officer emphasized that testing is simple, insured, and relevant for 2-3% of lung cancer cases. Last year, the drugs generated nearly $400 million in sales.
September 14, 2024
3 Articles